Karwacki-Neisius, Violetta http://orcid.org/0009-0006-6273-9814
Jang, Ahram
Cukuroglu, Engin
Tai, Albert http://orcid.org/0000-0001-7771-0850
Jiao, Alan
Predes, Danilo http://orcid.org/0000-0003-1864-0324
Yoon, Joon
Brookes, Emily http://orcid.org/0000-0003-2175-4349
Chen, Jiekai http://orcid.org/0000-0001-5168-7074
Iberg, Aimee
Halbritter, Florian http://orcid.org/0000-0003-2452-4784
Õunap, Katrin http://orcid.org/0000-0002-4594-6364
Gecz, Jozef http://orcid.org/0000-0002-7884-6861
Schlaeger, Thorsten M. http://orcid.org/0000-0002-1599-9908
Ho Sui, Shannan http://orcid.org/0000-0002-6191-4709
Göke, Jonathan http://orcid.org/0000-0002-0825-4991
He, Xi http://orcid.org/0000-0002-8093-7981
Lehtinen, Maria K. http://orcid.org/0000-0002-7243-2967
Pomeroy, Scott L.
Shi, Yang http://orcid.org/0000-0001-9713-1709
Article History
Received: 7 January 2023
Accepted: 12 January 2024
First Online: 21 February 2024
Competing interests
: Y.S. is a co-founder and board member of Alternative Bio (ABio). Y.S. is also a board member of Epigenica and a member of the Scientific Advisory Board of Epic Bio, the School of Life Sciences and Westlake Laboratory of Life Sciences and Biomedicine, Westlake University, China, and the Centre for Embryology and Healthy Development, Norway. Y.S. holds equity in Active Motif, K36 Therapeutics, Epic Bio, ABio and Epigenica. All other authors declare no competing interests.